TESAMORELIN.XYZ explains a lab-made copy of the hormone that tells the pituitary to release growth hormone. We sell nothing here.
Home›Research

What the Studies Show

Research
Keep in mind:
Almost all solid evidence comes from adults with HIV. The large trials were funded by the manufacturer, and the effects only lasted while people kept taking it.

Tesamorelin has been tested mainly against deep belly fat in people with HIV. Smaller studies have looked at fatty liver and at memory in older adults.

The Approval Trials

  • First phase 3 trial (N Engl J Med, 2007): 412 adults with HIV and extra belly fat took tesamorelin or placebo daily for 26 weeks. Visceral fat dropped by about 15% with tesamorelin and rose by 5% with placebo, and triglycerides fell. IGF-1 went up by about 81%.
  • Extension (AIDS, 2008): people who stayed on treatment kept about 18% less visceral fat after a full year, without worse blood sugar. In those switched to placebo, the fat came back.
  • Both trials combined (J Clin Endocrinol Metab, 2010): across 806 patients, tesamorelin reduced visceral fat but left the fat under the skin largely unchanged. Patients and doctors also rated the look of the belly as better.
  • Who benefits (Clin Infect Dis, 2012): the researchers compared people who lost at least 8% of their visceral fat with those who did not. In the first group, blood fats and blood sugar control improved, while in those who did not respond, blood sugar drifted slightly upwards.

Fat in the Liver

  • Pilot trial (JAMA, 2014): in 50 people with HIV, six months of tesamorelin cut both visceral fat and liver fat compared with placebo.
  • Fatty liver trial (Lancet HIV, 2019): 61 adults with HIV and fatty liver were treated for a year. Compared with placebo, liver fat fell by about 37% from where it started, and 35% of the tesamorelin group ended below the threshold for fatty liver, against 4% on placebo. An accompanying commentary called the results promising but asked for longer studies.

Memory and the Ageing Brain

In a 2012 trial at the University of Washington, 152 adults aged 55 to 87, some with mild memory problems, used tesamorelin or placebo for 20 weeks. The tesamorelin group did better on tests of planning and mental flexibility. A small 2026 pilot study of 22 people over 10 weeks found no clear changes on standard tests, though computer analysis of brain scans hinted at some differences.

Newer Work

A 2026 meta-analysis pooled four randomised trials with 909 patients. It confirmed less visceral fat, smaller waists and more lean mass, but also more people stopping early because of side effects. A trial called TRIUMPH, published as a protocol in 2026, is testing tesamorelin together with exercise in 100 older adults with HIV who are frail or at risk of frailty.

Gaps in the Evidence

  • The big trials ran for one year at most, so long-term heart outcomes are unknown.
  • Most participants were men with HIV, and few studies looked at anyone else.
  • Visceral fat returned once treatment stopped.
  • The liver and memory studies were small and need confirming.

Overall

Tesamorelin reliably shrinks deep belly fat in adults with HIV and may reduce liver fat too. Whether that leads to fewer heart attacks or better long-term health has never been shown, which is exactly the doubt European regulators raised.

References

  1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370. PMID 18057338
  2. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22:1719-1728. PMID 18690162
  3. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95:4291-4304. PMID 20554713
  4. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46:240-247. PMID 22298602
  5. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54:1642-1651. PMID 22495074
  6. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69:1420-1429. PMID 22869065
  7. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312:380-389. PMID 25038357
  8. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6:e821-e830. PMID 31611038
  9. Audsley J, Sasadeusz J, Lewin SR. Tesamorelin, liver fat, and NAFLD in the setting of HIV. Lancet HIV. 2019;6:e808-e809. PMID 31611037
  10. Stewart CE, French KP, Wright TJ, et al. The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci. 2026;44:100616. PMID 42382101
  11. Erlandson KM, Gustafson L, Johnson JE, et al. Tesamorelin as an adjunct to exercise for improving physical function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026;16:e120740. PMID 42419889
  12. Ditta AM, Naeem RM, Sami MM, et al. Efficacy and safety of tesamorelin in people living with HIV (PLWH) with lipodystrophy: a systematic review and meta-analysis. J Int Assoc Provid AIDS Care. 2026;25:23259582261475549. PMID 42538058